Gilead: Jefferies still a buyer
(CercleFinance.com) - On Monday an analyst at Jefferies confirmed his "Buy" recommendation on the Gilead stock, after the group presented new data.
"GILD presented new data for its HIV capsid at the Int'l AIDS Conf. Most notable: new PK data confirm potential for dosing every six months - a big improvement over daily therapy," the broker said.
Jefferies has confirmed its target price of 97 dollars for the share.
Copyright (c) 2020 CercleFinance.com. All rights reserved.
The information and analyses distributed by Cercle Finance are only intended as decision-making support for investors. Cercle Finance's responsibility may not be entailed, either directly or indirectly following the use of such information and analyses by readers. Any non-professional investor is recommended to consult a professional advisor before making any investment decision. This indicative information in no way constitutes any invitation to sell or buy securities.
"GILD presented new data for its HIV capsid at the Int'l AIDS Conf. Most notable: new PK data confirm potential for dosing every six months - a big improvement over daily therapy," the broker said.
Jefferies has confirmed its target price of 97 dollars for the share.
Copyright (c) 2020 CercleFinance.com. All rights reserved.
The information and analyses distributed by Cercle Finance are only intended as decision-making support for investors. Cercle Finance's responsibility may not be entailed, either directly or indirectly following the use of such information and analyses by readers. Any non-professional investor is recommended to consult a professional advisor before making any investment decision. This indicative information in no way constitutes any invitation to sell or buy securities.